| Name | Title | Contact Details |
|---|
Listening to your body is one thing, understanding what it is telling you is an altogether different story. Polar helps you get under the skin of your training. We put it down to a combination of expertise in sports, physiology and electronics, coupled with a deep understanding of customer needs. It`s no surprise then that we`ve been leading the way in technological innovations and heart rate monitors since 1977. And we cater for all levels of fitness by offering a comprehensive product range, along with essential support and advice. Everything from improving an athlete`s sports performance to helping people enjoy a healthier lifestyle, and aiding rehabilitation and weight management. This desire to be the best is made possible by ambitious and highly talented professionals who still believe as passionately in what we do today, as we did over 30 years ago. And our success is clear to see. Today, Polar employs 1200 people worldwide, has 26 subsidiaries globally and manages a distribution network supplying over 35,000 retail outlets in more than 80 countries. Now that`s what we call the power behind Polar.
Marimed Foundation is a Kaneohe, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NEO U is a live streaming and on demand platform for trainers and brands to scale to a world-wide audience. We host top fitness experts and workout concepts from around the world in our state-of-the-art fitness hub in Midtown Manhattan.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
Marcon Group Inc is a San Rafael, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.